-- 总部位于挪威的抗癌药物制造商Photocure周一发布新闻稿称，将采取一切手段，确保获得与中国江苏亚虹医药（SHA:688176）或亚思瑞斯制药公司（Asieris Pharmaceuticals）达成的许可协议的全部里程碑付款。 Photocure在周一的新闻稿中表示，由于中国批准了该公司的抗癌药物APL-1702，亚思瑞斯制药应向Photocure支付1100万美元的里程碑付款，但亚思瑞斯制药仅支付了其中的660万美元。 Photocure的新闻稿援引亚思瑞斯制药的话说，该产品获得的药品标签仅足以支付部分款项。 然而，这家挪威制药商表示，亚思瑞斯制药的说法“毫无根据”，并称里程碑付款已经达成。
Related Articles
Asia
Resolute Mining Says BlackRock Group Reduces Stake
Resolute Mining (ASX:RSG) received notice that BlackRock Group and its subsidiaries decreased their holdings in the company to 5.08% from 6.2%, according to a Monday filing with the Australian bourse.BlackRock Group now owns 108.7 million shares in the company, the filing said.
$ASX:RSG
Asia
Alkane Resources' March Quarter Production Beat Driven by Higher-Than-Modeled Head Grades, Euroz Hartleys Says
Alkane Resources (ASX:ALK) delivered a material production beat in the March quarter, driven mainly by higher-than-modeled head grades across its operations, a small beat on throughput at its Tomingley gold project in New South Wales, as well as higher recoveries at the Bjorkdal gold mine in Sweden, Euroz Hartleys said in an April 24 note.The company reported consolidated production of abut 45,800 ounces of gold equivalent, an early group record, Euroz Hartleys said.The equity research firm noted that Alkane Resources remains debt-free with the exception of AU$20 million in equipment financing, while the execution of an undrawn AU$110 million revolving facility and a AU$40 million contingent instrument facility provides liquidity to act fast on emerging opportunities.The company is on track to surpass the midpoint of fiscal 2026 guidance of 160,000 to 175,000 ounces of gold equivalent production at all-in sustaining costs of AU$2,600 to AU$2,900 per ounce. However, Euroz Hartleys expects softer quarter-over-quarter production in the three months through June due to lower head grades across the group.Euroz Hartleys kept a buy rating on the company while adjusting its price target to AU$2.53 from AU$2.50.
$ASX:ALK
Asia
Nextdc Launches AU$500 Million Retail Entitlement Offer
Nextdc (ASX:NXT) opened the retail portion of its fully underwritten 1-for-5.4 accelerated non-renounceable entitlement offer to raise about AU$1.5 billion in total, according to a Monday filing with the Australian bourse.The retail offer, expected to raise around AU$500 million, is priced at AU$12.70 apiece, the same price used in the institutional component, which recently closed and raised about AU$1 billion, per the filing.Eligible retail shareholders who fully exercise their entitlement may also apply for additional new shares up to 100% of their entitlement at the offer price under the top-up facility, the filing added.
$ASX:NXT